摘要
目的比较格列美脲与二甲双胍对代谢综合征(MS)患者的治疗效果。方法25例MS患者随机分为三组接受格列美脲、二甲双胍或二药合用治疗,比较三组治疗前后糖代谢、脂代谢、空腹胰岛素(FINS)、胰岛素抵抗指数(HO-MA-IR)、胰岛素敏感指数(IAI)的变化。结果①三组治疗后体质指数(BM I)下降(P<0.05);②治疗后三组空腹血糖(FBG)、餐后血糖(PBG)、糖化血红蛋白(HbA1 c)水平均较治疗前下降(P<0.05);③格列美脲组治疗后甘油三脂(TG)下降(P<0.05),二甲双胍组治疗后TG下降、高密度脂蛋白(HDL-C)升高(P<0.05);④治疗后三组的FINS水平均降低,但格列美脲组下降更显著(P<0.05);⑤三组治疗后HOMA-IR均降低,IAI均升高,格列美脲组IAI升高更显著(P<0.05)。结论格列美脲与二甲双胍均可有效改善MS患者的胰岛素抵抗,格列美脲改善胰岛素敏感性及降低高胰岛素血症方面优于二甲双胍。
Objective To compare the effect of glimepiride and mefformin in the treatment of metabolic syndrom （MS）. Methods One hundred and twenty - five paitents with MS were randomly assigned to receive glimepiride or mefformin or both glimepiride and mefformin. We compare the glucose metabolism ,lipid metabolism, fasting insulin levels（ FINS）, insulin resistance index （HOMA -IR）and insulin sensitivity index （IAI） before and after one year treatment among three groups. Results At one year,①the values of body mass index （BMI） were significantly reduced in all three group patients （ P 〈 0, 05 ） ; ② fasting blood glucose （ FBG ）, postprandial blood glucose （ PBG ） and glycosylated hemoglobin （HbAlc） were significantly decreased in all three group patients（ P 〈 0.05 ） ;③Triglyceride （TG） levels were significantly decreased in glimepiride group（ P 〈 0. 05 ）. TG levels were decreased and high - density lipoprotein -cholesterol（ HDL- C ）levels were increased significantly in mefformin group（ P 〈0.05） ;④the FINS were decreased in all three groups,but the decrease were the most significant in glimepiride group（ P 〈 0.05 ） ;⑤ HOMA - IR were decreased and IAI were increased in all three groups（ P 〈 0, 05 ）, but the increase in IAI was most significant in glimepride group. Conclusion Glimepiride and mefformine both can improve IR in MS patients , glimepiride is better than metforminc in improveing insulin sensitivity and reducing fasting hyperinsulinemia.
出处
《临床和实验医学杂志》
2006年第5期453-455,共3页
Journal of Clinical and Experimental Medicine
基金
国家十五攻关课题项目(2001BA702B01)提供部分资助
